23 results on '"Lannergard, A"'
Search Results
2. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals
- Author
-
Martinello, Marianne, Matthews, Gail, Fernando, Fay Fabián, Esteban, Juan I., Müllhaupt, Beat, Wiesch, Julian Schulze zur, Buggisch, Peter, Neumann-Haefelin, Christoph, Berg, Thomas, Berg, Christoph P., Schattenberg, Jörn M., Moreno, Christophe, Stauber, Rudolf, Lloyd, Andrew, Dore, Gregory, Applegate, Tanya, Ignacio, Juan, Garcia-Cehic, Damir, Gregori, Josep, Rodriguez-Frias, Francisco, Rando, Ariadna, Gozlan, Yael, Angelico, Mario, Andreoni, Massimo, Babudieri, Sergio, Bertoli, Ada, Cento, Valeria, Coppola, Nicola, Craxì, Antonio, Paolucci, Stefania, Parruti, Giustino, Pasquazzi, Caterina, Perno, Carlo Federico, Teti, Elisabetta, Vironet, C., Lannergård, Anders, Duberg, Ann-Sofi, Aleman, Soo, Gutteberg, Tore, Soulier, Alexandre, Gourgeon, Aurélie, Chevaliez, Stephane, Pol, Stanislas, Carrat, Fabrice, Salmon, Dominique, Kaiser, Rolf, Knopes, Elena, Gomes, Perpetua, de Kneght, Rob, Rijnders, Bart, Poljak, Mario, Lunar, Maja, Usubillaga, Rafael, Seguin_Devaux, Carole, Tay, Enoch, Wilson, Caroline, Wang, Dao Sen, George, Jacob, Kok, Jen, Pérez, Ana Belén, Chueca, Natalia, García-Deltoro, Miguel, Martínez-Sapiña, Ana María, Lara-Pérez, María Magdalena, García-Bujalance, Silvia, Aldámiz-Echevarría, Teresa, Vera-Méndez, Francisco Jesús, Pineda, Juan Antonio, Casado, Marta, Pascasio, Juan Manuel, Salmerón, Javier, Alados-Arboledas, Juan Carlos, Poyato, Antonio, Téllez, Francisco, Rivero-Juárez, Antonio, Merino, Dolores, Vivancos-Gallego, María Jesús, Rosales-Zábal, José Miguel, Ocete, María Dolores, Simón, Miguel Ángel, Rincón, Pilar, Reus, Sergi, De la Iglesia, Alberto, García-Arata, Isabel, Jiménez, Miguel, Jiménez, Fernando, Hernández-Quero, José, Galera, Carlos, Balghata, Mohamed Omar, Primo, Joaquín, Masiá, Mar, Espinosa, Nuria, Delgado, Marcial, von-Wichmann, Miguel Ángel, Collado, Antonio, Santos, Jesús, Mínguez, Carlos, Díaz-Flores, Felícitas, Fernández, Elisa, Bernal, Enrique, De Juan, José, Antón, José Joaquín, Vélez, Mónica, Aguilera, Antonio, Navarro, Daniel, Arenas, Juan Ignacio, Fernández, Clotilde, Espinosa, María Dolores, Ríos, María José, Alonso, Roberto, Hidalgo, Carmen, Hernández, Rosario, Téllez, María Jesús, Rodríguez, Francisco Javier, Antequera, Pedro, Delgado, Cristina, Martín, Patricia, Crespo, Javier, Becerril, Berta, Pérez, Oscar, García-Herola, Antonio, Montero, José, Freyre, Carolina, Grau, Concepción, Cabezas, Joaquin, Jimenez, Miguel, Rodriguez, Manuel Alberto Macias, Quilez, Cristina, Pardo, Maria Rodriguez, Muñoz-Medina, Leopoldo, Figueruela, Blanca, Howe, Anita Y.M., Rodrigo, Chaturaka, Cunningham, Evan B., Douglas, Mark W., Dietz, Julia, Grebely, Jason, Popping, Stephanie, Sfalcin, Javier Alejandro, Parczewski, Milosz, Sarrazin, Christoph, de Salazar, Adolfo, Fuentes, Ana, Sayan, Murat, Quer, Josep, Kjellin, Midori, Kileng, Hege, Mor, Orna, Lennerstrand, Johan, Fourati, Slim, Di Maio, Velia Chiara, Chulanov, Vladimir, Pawlotsky, Jean-Michel, Harrigan, P. Richard, Ceccherini-Silberstein, Francesca, and Garcia, Federico
- Published
- 2022
- Full Text
- View/download PDF
3. A 25-year retrospective analysis of factors influencing success of aluminum treatment for lake restoration
- Author
-
Agstam-Norlin, O., Lannergård, E.E., Rydin, E., Futter, M.N., and Huser, B.J.
- Published
- 2021
- Full Text
- View/download PDF
4. Optimization of aluminum treatment efficiency to control internal phosphorus loading in eutrophic lakes
- Author
-
Agstam-Norlin, O., Lannergård, E.E., Futter, M.N., and Huser, B.J.
- Published
- 2020
- Full Text
- View/download PDF
5. An evaluation of high frequency turbidity as a proxy for riverine total phosphorus concentrations
- Author
-
Lannergård, Emma E., Ledesma, José L.J., Fölster, Jens, and Futter, Martyn N.
- Published
- 2019
- Full Text
- View/download PDF
6. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial
- Author
-
Sandberg, Torsten, Skoog, Gunilla, Hermansson, Anna Bornefalk, Kahlmeter, Gunnar, Kuylenstierna, Nils, Lannergård, Anders, Otto, Gisela, Settergren, Bo, and Ekman, Gunilla Stridh
- Published
- 2012
- Full Text
- View/download PDF
7. The Hypervariable Region of Streptococcus pyogenes M Protein Escapes Antibody Attack by Antigenic Variation and Weak Immunogenicity
- Author
-
Lannergård, Jonas, Gustafsson, Mattias C.U., Waldemarsson, Johan, Norrby-Teglund, Anna, Stålhammar-Carlemalm, Margaretha, and Lindahl, Gunnar
- Published
- 2011
- Full Text
- View/download PDF
8. A Secreted Collagen- and Fibronectin-binding Streptococcal Protein Modulates Cell-mediated Collagen Gel Contraction and Interstitial Fluid Pressure
- Author
-
Lidén, Åsa, van Wieringen, Tijs, Lannergård, Jonas, Kassner, Anja, Heinegård, Dick, Reed, Rolf K., Guss, Bengt, and Rubin, Kristofer
- Published
- 2008
- Full Text
- View/download PDF
9. Vaccination of horses against strangles using recombinant antigens from Streptococcus equi
- Author
-
Waller, Andrew, Flock, Margareta, Smith, Ken, Robinson, Carl, Mitchell, Zoe, Karlström, Åsa, Lannergård, Jonas, Bergman, Rune, Guss, Bengt, and Flock, Jan-Ingmar
- Published
- 2007
- Full Text
- View/download PDF
10. Protective effect of vaccination with recombinant proteins from Streptococcus equi subspecies equi in a strangles model in the mouse
- Author
-
Flock, M., Karlström, Å., Lannergård, J., Guss, B., and Flock, J.-I.
- Published
- 2006
- Full Text
- View/download PDF
11. A fibronectin-binding protein from Streptococcus equi binds collagen and modulates cell-mediated collagen gel contraction
- Author
-
Lidén, Åsa, Karlström, Åsa, Lannergård, Jonas, Kalamajski, Sebastian, Guss, Bengt, Rubin, Kristofer, and Rydén, Cecilia
- Published
- 2006
- Full Text
- View/download PDF
12. Serum Amyloid A: A Novel Serum Marker For The Detection Of Systemic Inflammatory Response In Cystitis
- Author
-
LANNERGÅRD, A., FRIMAN, G., and LARSSON, A.
- Published
- 2003
- Full Text
- View/download PDF
13. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection
- Author
-
Wilcox, M. H., Gerding, D. N., Poxton, I. R., Kelly, C., Nathan, R., Birch, T., Cornely, O. A., Rahav, G., Bouza, E., Lee, C., Jenkin, G., Jensen, W., Kim, Y. -S., Yoshida, J., Gabryelski, L., Pedley, A., Eves, K., Tipping, R., Guris, D., Kartsonis, N., Playford G, Dorr M. -B., Mcgechie, D, Iredell, J, Allworth, A, Cheng, A, Choi, Nj, Thalhammer, F, Maieron, A, Wenisch, C, Meyer, B, Jacobs, F, Delmee, M, Peetermans, W, Giot, Jb, Munhoz, Al, Kallas, Eg, Ladeira, Jp, Bernstein, Cn, Grimard, D, Mcgeer, A, Poirier, A, Valiquette, L, Miller, M, Oughton, M, Trottier, S, Dolce, P, Smyth, D, Gambra, P, Palma, S, Rojas, L, Northland, R, Arellano, Mc, Perez, J, Barreto, Mf, Gomez, Jm, Ramirez, I, Correa, A, Onate, J, Rohacova, H, Stastnik, M, Zjevikova, A, Blazek, J, Kumpel, P, Petersen, Am, Gluud, Ll, Staugaard, Hm, Tvede, M, Glerup, H, Madsen, Sm, Helms, M, Naumann, R, Karthaus, M, Reinshagen, M, Raz, R, Giladi, M, Chowers, M, Bishara, J, Quirino, T, Castelli, F, Bassetti, M, Rizzardini, G, Vismara, E, Puoti, M, Viale, P, Menichetti, F, Cauda, R, Bonfanti, P, Franzetti, F, Gori, A, Minoli, L, Noriega, Er, Mills, Gd, Ritchie, S, Burns, A, Pithie, A, dos Santos RM, Aldomiro, F, Fernando, Pb, Rola, J, Reis, E, Van Zyl JH, Aboo, N, Richards, G, Hernandez, Mj, de Medrano VA, Prunonosa, Lm, Gonzalez, Jl, Reinoso, Jc, Martinez, Ar, Cisneros, Jd, Banos, Jr, Sheridan, R, Minton, J, Williams, J, Stanley, P, Guleri, A, Llewelyn, M, Todd, N, Barlow, G, Bacon, Ae, Baird, Im, Baxter, R, Zenilman, Jm, Beshay, M, Betts, Rf, Brettholz, Em, Buitrago, Mi, Carlson, Rw, Cook, Pp, Dupont, Hl, Foley, C, Freilich, B, Giron, Ja, Golan, Y, Green, S, Hall, Mc, Johnson, Dj, Jones, Rk, Graham, Dr, Kazimir, M, Keating, M, Brumble, Lm, Kumar, Pn, Liappis, Ap, Libke, R, Mehra, Pk, Overcash, Sj, Mullane, Km, Nguyen, Mh, Patel, Mc, Powers, Ck, Pullman, J, Keegan, J, Nepal, S, English, G, Ricci, Rl, Risi, Gf, Rodriguez, M, Schmitt, Cm, Sims, Md, Kamepalli, R, Tural, A, Vazquez, Ja, Alangaden, Gj, Weavind, Lm, Young, Ma, Chen, St, Liu, E, Nguyen, Hh, Alfonso, Tb, Muse, Dd, Orenstein, R, Yacyshyn, B, Gebhard, Re, Dinges, W, Bolton, M, Rubin, M, Kuemmerle, Jf, Limaye, Ap, Friedenberg, Ka, Hiemenz, Jw, Quadri, A, Martinez, Jv, Barcan, La, Cordova, E, Mykietiuk, A, Losso, M, Fedorak, Rn, Steiner, T, Gerson, M, Weiss, K, Dlouhy, P, Vitous, A, Benes, J, Husa, P, Knizek, P, Anttila, Vj, Broas, M, Camou, F, Postil, D, Launay, O, Corroyer-Simovic, B, Meynard, Jl, Schneider, S, Molina, Jm, Neau, D, Zalcman, G, Boutoille, D, Ostermann, H, Heinz, W, Reuter, S, Oren, I, Schiff, E, Umemoto, T, Masubuchi, T, Mukawa, K, Yasuda, K, Imokawa, S, Fukuda, K, Ohta, H, Harada, N, Fujii, S, Tamaki, S, Yasui, S, Furukawa, K, Takahashi, M, Uraoka, T, Watanabe, M, Ikehara, Y, Kodaira, M, Komatsu, H, Higashi, K, Taguchi, F, Ura, N, Serizawa, Y, Fukuchi, T, Ashikawa, T, Shabana, M, Okubo, M, Matsumoto, M, Kurihara, A, Miyasaka, E, Shimizu, M, Tominaga, H, Kubota, T, Kashiwazaki, M, Masuda, Y, Terasaki, S, Okafuji, H, Mieno, H, Urabe, T, Okamoto, E, Kajimura, M, Yamagishi, Y, Rydzewska, G, Mach, T, Ciechanowski, K, Podlasin, R, Tomasiewicz, K, Janczewska-Kazek, E, Czarnobilski, K, Halota, W, Gryglewska, B, Plesniak, R, Dabrowiecki, P, Lipowski, D, Simanenkov, V, Shcheglova, L, Uspenskiy, Y, Cheganov, A, Han, Ds, Kim, Js, Hong, Sp, Kim, Ti, Jang, Bi, Byeon, Js, Kim, E, Kim, Mj, Lee, J, Pai, H, Cheong, Hj, Lee, S, Loyarte, Ja, Gonzalez, Jc, Santiago, Eb, Lopez, Jr, Baranda, Jm, Viladomiu, As, Calbo, E, Lannergard, A, Falt, J, Gardlund, B, Andersson, Lm, Fraenkel, Cj, Rombo, L, Widmer, A, Chen, Yc, Sheng, Wh, Wang, Fd, Wang, Nc, Lee, Ch, Chen, Yh, Chuang, Yc, Unal, S, Ozaras, R, Esen, S, Ural, O, Ayaz, C, Sakarya, S, Celebi, A, Mistik, R, Bedimo, R, Bressler, A, Mckinley, Mj, Quirk, D, Talansky, Al, Agronin, Me, Akhrass, Fa, Ali, M, Alrabaa, Sf, Assi, Ma, Calfee, Dp, Carson, P, Mariani, Pg, Guerrero, D, Dubberke, Er, Hardi, R, Hazan-Steinberg, S, Itani, Km, Jauregui-Peredo, El, Kasabji, A, Hameed, M, Murillo, A, Odio, Aj, Shah, P, Braun, Ti, Slim, J, Sloan, L, Srinivasan, S, Tan, Mj, Clough, La, Herr, D, Miller, Lg, Dorfmeister, J, Khan, O, and Melik-Abrahamian, F.
- Subjects
0301 basic medicine ,Male ,Adolescent ,Adult ,Aged ,Aged, 80 and over ,Anti-Bacterial Agents ,Antibodies, Monoclonal ,Antibodies, Neutralizing ,Clostridium Infections ,Double-Blind Method ,Drug Therapy, Combination ,Female ,Humans ,Infusions, Intravenous ,Intention to Treat Analysis ,Kaplan-Meier Estimate ,Middle Aged ,Secondary Prevention ,Young Adult ,Clostridium difficile ,Clinical Trial, Phase III ,Antibiotics ,0302 clinical medicine ,Monoclonal ,80 and over ,030212 general & internal medicine ,Medicine (all) ,Neutralizing ,education.field_of_study ,Research Support, Non-U.S. Gov't ,General Medicine ,Multicenter Study ,Randomized Controlled Trial ,Combination ,Broadly Neutralizing Antibodies ,Intravenous ,medicine.medical_specialty ,Infusions ,medicine.drug_class ,030106 microbiology ,Population ,Placebo ,Antibodies ,03 medical and health sciences ,Pharmacotherapy ,Drug Therapy ,Internal medicine ,Journal Article ,medicine ,education ,Intention-to-treat analysis ,Clostridioides difficile ,business.industry ,Interim analysis ,Surgery ,Bezlotoxumab ,business - Abstract
BACKGROUND: Clostridium difficile is the most common cause of infectious diarrhea in hospitalized patients. Recurrences are common after antibiotic therapy. Actoxumab and bezlotoxumab are human monoclonal antibodies against C. difficile toxins A and B, respectively.METHODS: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials, MODIFY I and MODIFY II, involving 2655 adults receiving oral standard-of-care antibiotics for primary or recurrent C. difficile infection. Participants received an infusion of bezlotoxumab (10 mg per kilogram of body weight), actoxumab plus bezlotoxumab (10 mg per kilogram each), or placebo; actoxumab alone (10 mg per kilogram) was given in MODIFY I but discontinued after a planned interim analysis. The primary end point was recurrent infection (new episode after initial clinical cure) within 12 weeks after infusion in the modified intention-to-treat population.RESULTS: In both trials, the rate of recurrent C. difficile infection was significantly lower with bezlotoxumab alone than with placebo (MODIFY I: 17% [67 of 386] vs. 28% [109 of 395]; adjusted difference, -10.1 percentage points; 95% confidence interval [CI], -15.9 to -4.3; PCONCLUSIONS: Among participants receiving antibiotic treatment for primary or recurrent C. difficile infection, bezlotoxumab was associated with a substantially lower rate of recurrent infection than placebo and had a safety profile similar to that of placebo. The addition of actoxumab did not improve efficacy. (Funded by Merck; MODIFY I and MODIFY II ClinicalTrials.gov numbers, NCT01241552 and NCT01513239 .).
- Published
- 2017
- Full Text
- View/download PDF
14. 986. Inflammatory Cytokines in a Repeated Measures Prospective Case Study of Interferon-Induced Depression
- Author
-
Sundberg, Isak, primary, Lannergard, Anders, additional, Ramklint, Mia, additional, and Cunningham, Janet, additional
- Published
- 2017
- Full Text
- View/download PDF
15. Effect of pre-existing Hepatitis C NS3 Q80K variant in Genotype la and NS5A Y93H variant in Genotype 3 for interferon-free treatment combinations with direct antiviral agents (DAAs) : Real-life experience from a multicenter study in Sweden and Norway
- Author
-
Kileng, Hege, Kjellin, Midori, Bergfors, Assar, Duberg, Ann-Sofi, Wesslen, Lars, Danielsson, Astrid, Kristiansen, Magnhild G., Gutteberg, Tore, Lannergard, Anders, Lennerstrand, Johan, Kileng, Hege, Kjellin, Midori, Bergfors, Assar, Duberg, Ann-Sofi, Wesslen, Lars, Danielsson, Astrid, Kristiansen, Magnhild G., Gutteberg, Tore, Lannergard, Anders, and Lennerstrand, Johan
- Published
- 2016
16. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden
- Author
-
Lindstrom, Ida, Kjellin, Midori, Palanisamy, Navaneethan, Bondeson, Kare, Wesslen, Lars, Lannergard, Anders, Lennerstrand, Johan, Lindstrom, Ida, Kjellin, Midori, Palanisamy, Navaneethan, Bondeson, Kare, Wesslen, Lars, Lannergard, Anders, and Lennerstrand, Johan
- Abstract
Background: The future treatment of hepatitis C virus (HCV) infection will be combinations of direct-acting antivirals (DAAs) that not only target multiple viral targets, but are also effective against different HCV genotypes. Of the many drug targets in HCV, one promising target is the non-structural 5A protein (NS5A), against which inhibitors, namely daclatasvir, ledipasvir and ombitasvir, have shown potent efficacy. However, since HCV is known to have very high sequence diversity, development of resistance is a problem against but not limited to NS5A inhibitors (i.e. resistance also found against NS3-protease and NS5B non-nucleoside inhibitors), when used in suboptimal combinations. Furthermore, it has been shown that natural resistance against DAAs is present in treatment-naive patients and such baseline resistance will potentially complicate future treatment strategies. Methods: A pan-genotypic population-sequencing method with degenerated primers targeting the NS5A region was developed. We have investigated the prevalence of baseline resistant variants in 127 treatment-naive patients of HCV genotypes 1a, 1b, 2b and 3a. Results: The method could successfully sequence more than 95% of genotype 1a, 1b and 3a samples. Interpretation of fold resistance data against the NS5A inhibitors was done with the help of earlier published phenotypic data. Baseline resistance variants associated with high resistance (1000-50000-fold) was found in three patients: Q30H or Y93N in genotype 1a patients and further Y93H in a genotype 3a patient. Conclusion: Using this method, baseline resistance can be examined and the data could have a potential role in selecting the optimal and cost-efficient treatment for the patient., Funding: Uppsala-Orebro Regional Research Council, Selander Foundation
- Published
- 2015
- Full Text
- View/download PDF
17. Immune function in Swedish élite orienteers
- Author
-
Lannergard, A, Fohlman, J, Wesslen, L, Rolf, Christian, Friman, G, Lannergard, A, Fohlman, J, Wesslen, L, Rolf, Christian, and Friman, G
- Published
- 2001
18. Benign övergående hyperfosfatasemi. En orsak till stegring a alkaliskt fosfatas hos barn.
- Author
-
Lannergard, Anders, Dannaeus, Anders, Larsson, Anders, Lannergard, Anders, Dannaeus, Anders, and Larsson, Anders
- Published
- 2000
19. A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function
- Author
-
Viberg, Anders, primary, Lannergard, Anders, additional, Larsson, Anders, additional, Cars, Otto, additional, Karlsson, Mats O., additional, and Sandstrom, Marie, additional
- Published
- 2006
- Full Text
- View/download PDF
20. Immune function in Swedish élite orienteers.
- Author
-
Lannergard, A., Fohlman, J., Wesslen, L., Rolf, C., and Friman, G.
- Subjects
- *
CARDIAC arrest , *MYOCARDITIS , *IMMUNE response - Abstract
During 1979 1992 an increased frequency of sudden unexpected cardiac death (SUD) occurred among young male Swedish élite orienteers, Subacute-to-chronic myocarditis was found in 12/16 (75%) at autopsy and Chlamydia pneumoniae, or a cross-reacting agent, was suspected on the basis of diagnostic tests performed. Because myocarditis is an infrequent cause of SUD and clusters of SUD are rare, whereas Chlamydia pneumoniae infections are ubiquitous and seldom cause severe myocarditis, 119 top ranked é1ite orienteers (67 males and 52 females) and 36 highly trained male middle-distance runners and crosscountry skiers, serving as controls, underwent immunologic screening in an effort to reveal possible immune dysfunction. Except for two orienteers and one runner/skier who showed genetic C3-deficiency or IgA-deficiency, the results showed no significant differences between the orienteers and controls with respect to immunoglobulin levels, complement activation, lymphocyte subsets, including activated T lymphocytes, and sIL-2r-α, IL-1β, IL-6, TNF-α and sCD8, tested in the orienteers only were normal. However, IFN-γ was significantly higher in controls than in orienteers, who showed normal levels, whereas the orienteers had increased sELAM-1 and sICAM-1 levels. Finally, sIL-2 receptor-α was similarly elevated in orienteers and controls. We conclude that, with the tests employed, no immunologic disturbance could be revealed in the orienteers that may potentially have increased their susceptibility to myocarditis and SUD. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
21. Coherent catalogue with a selection of most promising NSWRM including results from MARG exchanges. Deliverable D2.1 of the EU Horizon 2020 project OPTAIN
- Author
-
Lemann, Tatenda, Fribourg-Blanc, Benoît, Magnier, Julie, Eichenberger, Joana, Strauch, Michael, Schürz, Christoph, Witing, Felix, Providoli, Isabelle, Szabó, Brigitta, Piroska, Kassai, Horel, Agota, Farkas-Ivanyi, Kinga, Gelybo, Gyorgyi, Braun, Péter, Kasa, Ilona, Molnar, Peter, Rozsa Forro, Eszter, Vida, Soma, Gielczewski, Marek, Piniewski, Mikołaj, Kardel, Ignacy, Bolewski, Tymoteusz, Kasperska-Wolowicz, Wieslawa, Glavan, Matjaž, Istenič, Darja, Griessler Bulc, Tjaša, Kramberger, Gregor, Kresenik, Katarina, Forio, Marie Anne Eurie, Goethals, Peter, Čerkasova, Natalja, Baltranaite, Egle, Magyla, Rimas, Titiskyte, Ligita, Monaco, Federica, Sali, Guido, Blankenberg, Anne-Grete, Krzeminska, Dominika, Skaalsveen, Kamilla, Fučik, Peter, Sitkova, Veronika, Zajíček, Antonín, Lagzdiņa, Ērika, Ernsteins, Raimonds, Skute, Arturs, Futter, Martyn, Lannergard, Emma, Collentine, Dennis, Amorsi, Natacha, Van den Brink, Cors, De Vries, Alma, Nesheim, Ingrid, Enge, Caroline, and Volk, Martin
- Subjects
NSWRM ,H2020 ,OPTAIN ,WOCAT ,NWRM ,water retention ,sustainable land management ,agriculture - Abstract
Deliverable report D2.1 of the EU Horizon 2020 Project OPTAIN (Grant agreement No. 862756) To gather and organise the knowledge collected and created by OPTAIN on NSWRM, the Work Package 2 developed a catalogue of NSWRM. It presents each NSWRM considered in the project and contains all the associated information. The objective of D2.1 is to make qualitative and quantitative information on each specific measure available to various stakeholder groups, like all end users and NSWRM implementers. It enables to allow them to select, design and implement one or more NSWRM on their farm (or territory), or extract specific data and information they need for supporting the development and promotion of NSWRM use. Summary During the first reporting period of the H2020 project OPTAIN, the task 2.1 partners focused on framing the concept of Natural Small Water Retention Measures (NSWRM) and on identifying and documenting existing and underutilised NSWRM in all 14 case studies (CS) of the project. Therefore, a systematic approach was developed involving all relevant stakeholder groups in Multi Actor Reference Groups (MARG), comprising the following steps: identification of existing or potentially suitable measures, prioritisation of measures with a high potential in the local context of the different case studies, selection of a set of 3 to 7 measures per case study, which are relevant for the case studies and the OPTAIN project. Once the NSWRM have been selected, all case study implementers started to collect data on their individual measures and to document them by using the World Overview of Conservation Approaches and Technologies (WOCAT) questionnaire on Sustainable Land Management (SLM) Technologies, thus generating a standardised factsheet of each measure. All entered data on the WOCAT SLM database will then be linked to the Natural Water Retention Measure (NWRM) platform. The OPTAIN catalogue will be accessible from both websites as well as through the project’s own “Learning Environment” which will include a section dedicated to OPTAINs catalogue of NSWRM. Overall, the prioritization in the 14 case studies resulted in 66 selected NSWRM. The case study teams started documenting these selected NSWRM with the World Overview of Conservation Approaches and Technologies (WOCAT) Technology questionnaire, including description and classification, technical specification, implementation inputs and costs, natural and human environment, as well as ecological, socio-economic and socio-cultural impacts. To help in this process, a two-day virtual WOCAT training for all case study teams was organised and conducted by the task 2.1 team. In parallel, the task 2.1 partners conducted an analysis of the commonalities and differences between both WOCAT and NWRM.eu databases to provide an integrated view. The result of this analysis was d that there are only a few differences and a smooth integration could be possible. All entered data on the WOCAT global SLM database (https://qcat.wocat.net) will thus be linked to the NWRM platform (http://nwrm.eu/).
- Published
- 2022
- Full Text
- View/download PDF
22. Tailored environmental and socio-economic performance indicators for selected measures. Deliverable D2.2 of the EU Horizon 2020 project OPTAIN
- Author
-
Krzeminska, Dominika, Monaco, Federica, Strauch, Michael, Schürz, Christoph, Lemann, Tatenda, Eichenberger, Joana, Szabó, Brigitta, Piroska, Kassai, Horel, Agota, Farkas-Ivanyi, Kinga, Kasa, Ilona, Molnar, Peter, Rozsa Forro, Eszter, Gielczewski, Marek, Kasperska-Wolowicz, Wieslawa, Glavan, Matjaž, Kramberger, Gregor, Kresenik, Katarina, Forio, Marie Anne Eurie, Goethals, Peter, Čerkasova, Natalja, Baltranaite, Egle, Magyla, Rimas, Titiskyte, Ligita, Blankenberg, Anne-Grete, Fučik, Peter, Sitkova, Veronika, Lagzdiņa, Ērika, Ernsteins, Raimonds, Skute, Arturs, Futter, Martyn, Lannergard, Emma, Collentine, Dennis, Fribourg-Blanc, Benoit, Volk, Martin, and Witing, Felix
- Subjects
environmental performance ,Multi-Actor-Reference Groups (MARG) ,NSWRM ,socio-economic performance ,H2020 ,OPTAIN ,indicators - Abstract
Deliverable report D2.2 of the EU Horizon 2020 Project OPTAIN (Grant agreement No. 862756). List of tailored and case-specific performance indicators (environmental and socio-economical) that help to evaluate the effectiveness of NSWRM monitored (existing measures) and modelled (potential future measures) in the OPTAIN case studies as well as used to establish a common language across project members and activities and to facilitate the knowledge sharing with stakeholders and the wider dissemination of project results. Summary: The content of this deliverable addresses the activities of the task 2.2 “Identification of performance indicators for the selected NSWRM” within the H2020 project OPTAIN. The core purpose of the task is to develop a customized set of indicators that allow assessing the effectiveness of selected (either existing or potential future) Natural/Small Water Retention Measures (NSWRMs) in and across the OPTAIN case studies (CS). The relevance of specific NSWRMs to face local challenges, their multifunctional nature and the manifold impacts they may have in the territory require identifying key elements that easily resume such features, while being flexible and adaptable enough to be used in different contexts. Therefore, task 2.2 elaborated a pathway to produce a list of Performance Indicators (PI), to set the focus for model parametrisation at different scales as well as to ensure an appropriate model setup and utilisation of modelling outcomes (WP4, WP5). For this reason, the screening, selection and tailoring of the most relevant indicators, to be used as PI, have been conducted from both the environmental (EPIs) and socio-economic (SPIs) points of view. The selection process was built at the interface between science and society, in a fruitful process of knowledge co-creation and sharing. As such, agreed lists of indicators can be used to support the harmonized approach of OPTAIN by establishing a common language across project members and activities, favour the understanding and the comparison of modelling results across CS, facilitating the dialogue with stakeholders and the wider dissemination of project results. The methodology followed to outline the customized list of indicators, to be used as PIs, was based upon the initial contribution of scientific / academic partners’ expertise to compile all the potential or candidate indicators and preselect the most relevant ones for the selected NSWRMs. As a result, we ended up with short lists of both environmental (25) and socio-economic (17) indicators that cover the most relevant issues of the OPTAIN case studies. In the second instance a participative approach involved local research teams and stakeholders in the valuation, adjustment and prioritisation of the most important indicators, also owing to the intensive consultation with OPTAINs Multi-Actor-Reference Groups (MARG). Based on the feedback obtained, the task 2.2 partners conducted an analysis of the commonalities and differences between CSs and scales. This allowed drawing the conclusion that, despite CS are experiencing diverse challenges, the most important issues covered by the selected indicators, and priorities given are very similar. Finally, for comparison purposes across CSs, a common set of PIs is proposed, including first discussions on the best way to represent selected PIs based on monitoring and/or modelling results to be available in CS.
- Published
- 2022
- Full Text
- View/download PDF
23. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.
- Author
-
Lindström I, Kjellin M, Palanisamy N, Bondeson K, Wesslén L, Lannergard A, and Lennerstrand J
- Subjects
- Antiviral Agents therapeutic use, Carbamates, Drug Resistance, Viral genetics, Genotype, Imidazoles therapeutic use, Mutation, Missense, Phylogeny, Polymerase Chain Reaction methods, Prevalence, Protease Inhibitors therapeutic use, Pyrrolidines, Sequence Analysis, Sweden epidemiology, Valine analogs & derivatives, Antiviral Agents pharmacology, Hepacivirus drug effects, Hepacivirus genetics, Hepatitis C virology, Hepatitis C, Chronic virology, Polymorphism, Genetic, Viral Nonstructural Proteins antagonists & inhibitors, Viral Nonstructural Proteins genetics
- Abstract
Background: The future treatment of hepatitis C virus (HCV) infection will be combinations of direct-acting antivirals (DAAs) that not only target multiple viral targets, but are also effective against different HCV genotypes. Of the many drug targets in HCV, one promising target is the non-structural 5A protein (NS5A), against which inhibitors, namely daclatasvir, ledipasvir and ombitasvir, have shown potent efficacy. However, since HCV is known to have very high sequence diversity, development of resistance is a problem against but not limited to NS5A inhibitors (i.e. resistance also found against NS3-protease and NS5B non-nucleoside inhibitors), when used in suboptimal combinations. Furthermore, it has been shown that natural resistance against DAAs is present in treatment-naïve patients and such baseline resistance will potentially complicate future treatment strategies., Methods: A pan-genotypic population-sequencing method with degenerated primers targeting the NS5A region was developed. We have investigated the prevalence of baseline resistant variants in 127 treatment-naïve patients of HCV genotypes 1a, 1b, 2b and 3a., Results: The method could successfully sequence more than 95% of genotype 1a, 1b and 3a samples. Interpretation of fold resistance data against the NS5A inhibitors was done with the help of earlier published phenotypic data. Baseline resistance variants associated with high resistance (1000-50,000-fold) was found in three patients: Q30H or Y93N in genotype 1a patients and further Y93H in a genotype 3a patient., Conclusion: Using this method, baseline resistance can be examined and the data could have a potential role in selecting the optimal and cost-efficient treatment for the patient.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.